Page last updated: 2024-12-11
chloride of pseudoisocyanine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5717105 |
CHEMBL ID | 576409 |
CHEBI ID | 38004 |
MeSH ID | M0327493 |
Synonyms (31)
Synonym |
---|
2,2'-quinocyanine chloride |
1,2'-cyanine chloride |
n,n'-diethylpseudoisocyanine |
nsc97374 |
diethylcyanine |
2,2'-cyanine chloride |
pseudoisocyanine chloride |
2402-42-8 |
pseudoisocyanine diethyl chloride |
n,n'-diethylpseudoisocyanine chloride |
1-ethyl-2-[(1-ethyl-2(1h)-quinolinylidene)methyl]quinolinium chloride |
1,1'-diethyl-2,2'-cyanine chloride |
CHEBI:38004 , |
1-ethyl-2-{[1-ethylquinolin-2(1h)-ylidene]methyl}quinolinium chloride |
CHEMBL576409 |
AKOS003601262 |
HMS2172F09 |
quinolinium, 1-ethyl-2-((1-ethyl-2(1h)-quinolinylidene)methyl)-, chloride |
einecs 219-279-7 |
1-ethyl-2-((1-ethyl-1,2-dihydro-2-quinolylidene)methyl)quinoliniumchloride |
unii-vxj7avj43d |
nsc 97374 |
vxj7avj43d , |
quinolinium, 1-ethyl-2-((1-ethyl-2(1h)-quinolinylidene)methyl)-, chloride (1:1) |
(2e)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylidene]quinoline;chloride |
SR-01000391515-1 |
sr-01000391515 |
Q27117339 |
nsc-97374 chloride |
1-ethyl-2-((1-ethyl-2(1h)-quinolylidene)methyl)quinolinium chloride |
quinolinium,1-ethyl-2-[(1-ethyl-2(1h)-quinolinylidene)methyl]-,chloride |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
1,1'-diethyl-2,2'-cyanine halide | |
organic chloride salt | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (66)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 35.4813 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 44.9647 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID504841 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 19.9526 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.3313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 5.5756 | 0.0184 | 6.8060 | 14.1254 | AID624172; AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
BRCA1 | Homo sapiens (human) | Potency | 3.9811 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
WRN | Homo sapiens (human) | Potency | 44.6684 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.1187 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 9.2000 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 1.5470 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.1623 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 7.9433 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 1.7783 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 22.3872 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
PINK1 | Homo sapiens (human) | Potency | 2.8184 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 18.9895 | 0.2239 | 11.2451 | 35.4813 | AID624173; AID720569; AID720584 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 3.9811 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
67.9K protein | Vaccinia virus | Potency | 12.5893 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
Parkin | Homo sapiens (human) | Potency | 2.8184 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 70.7946 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
pyruvate kinase | Leishmania mexicana mexicana | Potency | 14.1254 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
IDH1 | Homo sapiens (human) | Potency | 6.5131 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 2.9093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 25.1189 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 3.1623 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 14.1254 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
DNA polymerase beta | Homo sapiens (human) | Potency | 15.8489 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 39.8107 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.7943 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
snurportin-1 | Homo sapiens (human) | Potency | 89.1251 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 89.1251 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 84.9214 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 56.2341 | 0.1298 | 10.8331 | 32.6090 | AID493005 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 5.8655 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
Vpr | Human immunodeficiency virus 1 | Potency | 22.3872 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.5849 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 3.9811 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 16.5044 | 0.0580 | 10.6949 | 26.6086 | AID602310; AID651812; AID651813 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 12.5893 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 5.6234 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 7.9433 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 56.2341 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
Alpha-synuclein | Homo sapiens (human) | Potency | 11.2202 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 10.6101 | 1.0000 | 10.4756 | 28.1838 | AID1457; AID901 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 10.0000 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 26.0989 | 0.0757 | 8.4742 | 29.0628 | AID602233; AID686980 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
nonstructural protein 1 | Influenza A virus (A/California/07/2009(H1N1)) | IC50 (µMol) | 12.8460 | 0.2000 | 24.4540 | 100.0000 | AID504329 |
sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | IC50 (µMol) | 2.0925 | 1.0810 | 2.6352 | 4.7700 | AID851; AID856 |
eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 (µMol) | 33.7653 | 1.1500 | 12.6200 | 25.6529 | AID855 |
eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 33.7653 | 1.1500 | 12.6200 | 25.6529 | AID855 |
rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 46.4600 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | IC50 (µMol) | 10.6000 | 0.1100 | 11.3862 | 67.2000 | AID690 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Activation Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | EC50 (µMol) | 999.0000 | 0.5500 | 33.7339 | 74.0000 | AID696 |
streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 78.0425 | 0.0600 | 8.9128 | 130.5170 | AID1902; AID1914 |
Estrogen receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 150.0000 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
Estrogen receptor beta | Rattus norvegicus (Norway rat) | EC50 (µMol) | 150.0000 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Other Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glycogen synthase kinase-3 alpha | Homo sapiens (human) | AC50 | 66.1400 | 0.0135 | 29.7434 | 171.7000 | AID463203 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (114)
Molecular Functions (36)
Ceullar Components (35)
Bioassays (13)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |